Enclomiphene vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EnclomipheneGLP-1 / Weight Loss Agonists
Survodutide- Summary
- Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- 5-7 days (long half-life; accumulates)
- ~7 days
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 12.5-25 mg per day
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once daily or every other day
- Once weekly
- Key Benefits
- Restores testosterone to normal range without exogenous androgen administration
- Preserves or increases sperm production and fertility
- Maintains testicular volume (unlike TRT which causes testicular atrophy)
- LH and FSH levels rise, indicating intact HPG axis function
- Option for hypogonadal men desiring fertility
- Oral administration (no injection required)
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Visual disturbances (rare but class-related SERM effect)
- Mood changes or irritability
- Hot flashes
- Elevated estradiol in some users
- +2 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —